Design, delivery and efficacy testing of therapeutic nucleic acids used to inhibit hepatitis C virus gene expression in vitro and in vivo

doi:10.3748/wjg.v6.i5.626

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 5

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2481)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-1) series.

Item

Count

PDF

196

HTML

1837

Figures (1-4)

256

Tables (1-1)

192

Sum=2481

Oct 15, 2000 (publication date) through Nov 20, 2024

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastroenterol. Oct 15, 2000; 6(5): 626-629
Published online Oct 15, 2000. doi: 10.3748/wjg.v6.i5.626

Full Size Figure Download Figure

Figure 3 Modified hammerhead RZ and HCV target sequence. The G_16.2,C_16.1, A₁₇ recognition site (nts. 346-348), in which cleavage occurs, is marked by an arrow. All nucleotides are 2’-O-ally l-ribonucleotides except G₅, A₆, G₈ and G₁₂ (light gray), which are unmodified ribonucleotides. The position of the A to l exchange (medium gray) and the start AUG of the HCV template are indicated.

Citation: Caselmann WH, Serwe M, Lehmann T, Ludwig J, Sproat BS, Engels JW. Design, delivery and efficacy testing of therapeutic nucleic acids used to inhibit hepatitis C virus gene expression in vitro and in vivo. World J Gastroenterol 2000; 6(5): 626-629
URL: https://www.wjgnet.com/1007-9327/full/v6/i5/626.htm
DOI: https://dx.doi.org/10.3748/wjg.v6.i5.626